↓ Skip to main content

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer

Overview of attention for article published in Advances in Therapy, May 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (57th percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
22 Mendeley
Title
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Published in
Advances in Therapy, May 2016
DOI 10.1007/s12325-016-0351-4
Pubmed ID
Authors

Axel S. Merseburger, Marie C. Hupe

Abstract

Androgen deprivation therapy (ADT) is the mainstay palliative treatment for men with locally advanced and metastatic prostate cancer, and aims to reduce testosterone to levels obtained by surgical castration. Use of gonadotropin-releasing hormone (GnRH) agonists predominates among the ADT options. The GnRH agonist, triptorelin is a first-line hormonal therapy that has demonstrated efficacy and safety in clinical trials of patients with locally advanced non-metastatic or metastatic disease. Sustained-release 1-, 3- and 6-month formulations of triptorelin, administered intramuscularly or subcutaneously, have been developed to provide improved flexibility and convenience for the patient. Head-to-head studies of GnRH agonists are lacking in the field of prostate cancer. Despite the inevitable progression to castration-resistant prostate cancer (CRPC) in most patients receiving ADT, monitoring of testosterone levels needs to improve in routine practice and physicians should not overlook the benefits of continued ADT in their patients when introducing one of the various new treatment options for CRPC. For improved survival outcomes, there remains a need to tailor ADT treatment regimens, novel hormonal agents and chemotherapy according to the individual patient with advanced prostate cancer.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 22 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 23%
Unspecified 4 18%
Other 4 18%
Researcher 4 18%
Student > Bachelor 2 9%
Other 3 14%
Readers by discipline Count As %
Medicine and Dentistry 8 36%
Unspecified 4 18%
Agricultural and Biological Sciences 3 14%
Biochemistry, Genetics and Molecular Biology 3 14%
Chemistry 2 9%
Other 2 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2016.
All research outputs
#6,771,951
of 12,494,919 outputs
Outputs from Advances in Therapy
#381
of 1,077 outputs
Outputs of similar age
#108,868
of 265,912 outputs
Outputs of similar age from Advances in Therapy
#16
of 53 outputs
Altmetric has tracked 12,494,919 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,077 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,912 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.